A first-in-human study of 11C-MTP38, a novel PET ligand for phosphodiesterase 7
Open Access
- 10 February 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 48 (9), 2846-2855
- https://doi.org/10.1007/s00259-021-05235-0
Abstract
Purpose: Phosphodiesterase 7 (PDE7) is an enzyme that selectively hydrolyses cyclic adenosine monophosphate, and its dysfunction is implicated in neuropsychiatric diseases. However, in vivo visualization of PDE7 in human brains has hitherto not been possible. Using the novel PET ligand 11C-MTP38, which we recently developed, we aimed to image and quantify PDE7 in living human brains. Methods: Seven healthy males underwent a 90-min PET scan after injection of 11C-MTP38. We performed arterial blood sampling and metabolite analysis of plasma in six subjects to obtain a metabolite-corrected input function. Regional total distribution volumes (VTs) were estimated using compartment models, and Logan plot and Ichise multilinear analysis (MA1). We further quantified the specific radioligand binding using the original multilinear reference tissue model (MRTMO) and standardized uptake value ratio (SUVR) method with the cerebellar cortex as reference. Results: PET images with 11C-MTP38 showed relatively high retentions in several brain regions, including in the striatum, globus pallidus, and thalamus, as well as fast washout from the cerebellar cortex, in agreement with the known distribution of PDE7. VT values were robustly estimated by two-tissue compartment model analysis (mean VT = 4.2 for the pallidum), Logan plot, and MA1, all in excellent agreement with each other, suggesting the reversibility of 11C-MTP38 binding. Furthermore, there were good agreements between binding values estimated by indirect method and those estimated by both MRTMO and SUVR, indicating that these methods could be useful for reliable quantification of PDE7. Because MRTMO and SUVR do not require arterial blood sampling, they are the most practical for the clinical use of 11C-MTP38-PET. Conclusion: We have provided the first demonstration of PET visualization of PDE7 in human brains. 11C-MTP38 is a promising novel PET ligand for the quantitative investigation of central PDE7.Keywords
Funding Information
- Japan Society for the Promotion of Science (19K17101)
This publication has 24 references indexed in Scilit:
- Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developmentsBritish Journal of Pharmacology, 2012
- 101 Labeled Brain Images and a Consistent Human Cortical Labeling ProtocolFrontiers in Neuroscience, 2012
- Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissuesNeuropharmacology, 2010
- Cyclic Nucleotide Phosphodiesterases: Molecular Regulation to Clinical UsePharmacological Reviews, 2006
- Linearized Reference Tissue Parametric Imaging Methods: Application to [11C]DASB Positron Emission Tomography Studies of the Serotonin Transporter in Human BrainJournal of Cerebral Blood Flow & Metabolism, 2003
- Whole Brain Segmentation: Automated Labeling of Neuroanatomical Structures in the Human BrainNeuron, 2002
- Differential distribution of cAMP‐specific phosphodiesterase 7A mRNA in rat brain and peripheral organsSynapse, 2001
- Graphical Analysis of Reversible Radioligand Binding from Time—Activity Measurements Applied to [N-11C-Methyl]-(−)-Cocaine PET Studies in Human SubjectsJournal of Cerebral Blood Flow & Metabolism, 1990
- Effects of Temporal Sampling, Glucose Metabolic Rates, and Disruptions of the Blood—Brain Barrier on the FDG Model with and without a Vascular Compartment: Studies in Human Brain Tumors with PETJournal of Cerebral Blood Flow & Metabolism, 1986
- A new look at the statistical model identificationIEEE Transactions on Automatic Control, 1974